Curis Lifesciences IPO: Price, GMP, Analysis, And Details

Curis Lifesciences IPO- Company Analysis

Curis Lifesciences IPO under the SME IPO category is a bookbuild issue of Rs. 27.52 Cr by Curis Lifesciences Ltd., and is engaged in the manufacturing and marketing of pharmaceutical formulations for domestic and international markets. It is run under the brand name Loreto Pharmaceuticals.

It focuses on generic formulations, contract manufacturing, and third-party production to cater to hospitals, distributors, and government bodies. The company has also moved into regulated and semi-regulated markets and adhered to international quality standards.

Curis Lifesciences IPO Details

The Curis Lifesciences IPO date is on 07 November 2025, and its initial public offering will end on 11 Nov with IPO allotment on Nov 12, and refund initiation on Nov 13, 2025.

The Rs. 27.52 crore new SME IPO comprises a wholly fresh issue of 0.22 crore shares.

The Curis Lifesciences IPO listing date (expected) might be on Friday, Nov 14, 2025, and listing at the NSE and SME. 

The Curis Lifesciences IPO price band is Rs. 120 to Rs. 128.

IPO Timetable (Tentative)

Events	Date
IPO Opening Date	Nov 07, 2025
IPO Closing Date	Nov 11, 2025
IPO Allotment Date	Nov 12, 2025
Refund Initiation	Nov 13, 2025
IPO Listing Date	Nov 14, 2025

 

Click to open demat account and apply for the IPO.

 

 

Company Financials

(Amount in Cr)

Period Ended	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	42.53	33.88	29.75
Total Income	49.65	35.87	36.42
PAT	6.11	4.87	1.88
EBITDA	9.54	8.39	3.28
Net Worth	16.23	5.87	1.01
Reserves and Surplus	10.29	5.37	0.51
Total Borrowing	15.62	17.09	16.19

 

Cash Flows

(Amount in lac)

Net Cash Flow	31 Dec 2024	31 Mar 2024	31 Mar 2023
Net Cash Flow Operating Activities	(232.73)	28	334.64
Net Cash Flow Investing Activities	(12.65)	(6.16)	(54.72)
Net Cash Flow Financing Activities	258.51	4.68	(275.78)

Revenue Bifurcation

(Source: RHP)

The Objective of the Issue

The company desires to use the Net Proceeds from the Issue to fulfill its following goals:

• Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities. ~ Rs. 2.44 Cr.

• Capital Expenditure towards Construction of a Storage Facility. ~ Rs. 3.62 Cr.

• Pre-payment/Repayment of outstanding Secured Loans. ~ Rs. 1.86 Cr.

• Product Registrations in other countries. ~ Rs. 2.69 Cr.

• Funding our Working Capital Requirements. ~ Rs. 11.25 Cr.

• General corporate purposes. 

Listed Peers of Curis Lifesciences Ltd. 

Company Name	Face Value (Rs. )	EPS (Rs. )	P/E Ratio (x)
Sotac Pharmaceuticals Ltd.	10	4.32	27.49
Lincoln Pharmaceuticals Ltd.	10	41.11	13.42

 

Valuation

KPI	Value (31 Dec 2024)
EBITDA Margin	24.10%
PAT Margin	14.37%
ROE	49.34%
ROCE	26.48%
Debt to Equity Ratio	1.04

 

 

Evaluation of P/E Ratio

Considering the period ended on FY 2024 with an EPS of Rs. 8.52 from the last year, the resulting P/E ratio is 15.02x.

Explore the Shining Tools IPO.

 

IPO's Strengths

• Steady growth in revenue and profit.

• Solid history of promotion in the market and the industry.

• Coverage of multiple therapeutic sectors.

• Operating a manufacturing unit with necessary quality approvals.

• Expanding domestic and foreign client base.

IPO’s Weaknesses

•  Dependence on a small number of clients for particular products.

•  Complicated and competitive market.

•  High capital needed for sustaining operations.

• Risks of price volatility in raw materials and adverse exchange rates.
  
  

Curis Lifesciences IPO GMP (Grey Market Premium)

Curis Lifesciences IPO GMP today is Rs. 0, as of 04 Nov 2025 at the time of writing this information.

Curis Lifesciences IPO Summary

The Curis Lifesciences IPO has a market maker portion size of 108000 Shares (Rs. 1.38 Cr).

IPO Opening & Closing Date	07 Nov, 2025 to 11 Nov, 2025
Face Value	Rs. 10 per Share
Issue Price	Rs. 120 to Rs. 128 per Share.
Lot Size	1000 Shares
Issue Size	21,50,000 Shares (Rs. 27.52 Cr)
Offer for Sale	-
Fresh Issue	21,50,000 Shares (Rs. 27.52 Cr)
Listing at	NSE, SME
Issue Type	Bookbuild Issue IPO
Registrar	MUFG Intime India Pvt. Ltd.

 

 IPO Lot Details 

Retail investors can invest in a minimum and maximum of 2 Lots (2000 Shares) for Rs. 2,56,000 and in multiples thereof, while for S-HNI investors, the minimum Lot is 3 (3000 Shares) for Rs. 3,84,000.

Minimum Lot Investment (Retail)	2 Lots
Maximum Lot Investment (Retail)	2 Lots
S-HNI (Min)	3 Lots

 

Curis Lifesciences IPO Allotment Status

To check the Curis Lifesciences IPO Allotment Status, visit the official Registrar’s website or the BSE website. Below are the website links for you.

Using BSE Website - ​BSE IPO allotment status

Promoters And Management of Curis Lifesciences Ltd.

• Mr. Dharmesh Dashrathbhai Patel.

• Mr. Siddhant Jayantibhai Pawasia.

• Mr. Piyush Gordhanbhai Antala.

• Mr. Jaimik Mansukhbhai Patel.

Pre-Issue Promoter Shareholding	92.68%
Post-Issue Promoter Shareholding	68.03%

 

IPO Lead Managers

• Finaax Capital Advisors Private Limited.

 

Dividend Policy

The company has not declared a dividend during the last three financial years.

Conclusion

With an emphasis on precision formulation manufacturing and solid financial metrics, Curis Lifesciences Ltd. is a developing pharmaceutical competitor.  Strong profitability and effective operations are demonstrated by the RONW of 84.12%. Curis Lifesciences is a notable SME IPO to monitor because of its steady growth, seasoned promoters, and expansion aspirations, even though the IPO pricing and GMP have not yet been disclosed.

 

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO. 

You must consult your financial advisor before making any financial decisions. 

To Apply for the IPO, Click Here.

To Read the Prospectus of the Company Click Here to Download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.